Early in a shift, a hospital pharmacist opens the ordering system and finds that a drug costing pennies a packet cannot be obtained at any price the trust would normally contemplate. Nothing about the moment is dramatic. Aspirin is hardly a frontier therapy. Yet freedom of information responses from English trusts suggest the scene was common between late 2025 and early 2026. Of the trusts that answered, 26 of 42 reported aspirin disruption, 13 of 42 reported co-codamol shortages and 7 of 43 struggled to secure ramipril. Kent Community Health NHS Trust reported problems with all three.

Earlier shortages tended to involve specialised treatments, such as those for ADHD and epilepsy. The move towards ordinary generics matters because these are the products on which routine care depends. They are cheap, high volume and low margin, which gives manufacturers little reason to hold spare capacity and gives buyers little leverage when something goes wrong. Trade friction, conflict and production constraints elsewhere in the world arrive in a pharmacy store room as a missing box.

The more telling finding concerns what the NHS knows about its own position. Some 92 per cent of responding trusts had no formal contingency plan for medicine shortages, and 82 per cent had not reported ongoing shortages to national bodies. The explanation lies in the rules. Manufacturers must tell health authorities about impending supply problems. Trusts carry no equivalent duty. The centre therefore sees the supply side of the market and has a patchy view of the ward, which is where a shortage becomes a clinical decision.

That gap complicates official reassurance. NHS England rates this operational risk at 16 out of 25, and independent analysis argues the score understates the threat, noting that the stated aim is to reduce it. A rating that improves because few trusts report problems offers no comfort. It measures the quality of the data as much as the quality of the supply.

The costs are already visible. Supply instability consumes pharmacy and medical time on substitutions, communication with prescribers and checks that patients are not harmed by a change of product. At least one trust paid inflated market prices for ramipril to avoid gaps in treatment for people at cardiovascular risk. In a service under tight financial constraints, that is money diverted from elsewhere. It also creates a quiet inequity, because trusts with more headroom can pay for stock while others cannot, and patient access starts to vary by locality without anyone having decided that it should.

The Department of Health and Social Care points to Serious Shortage Protocols for ramipril and says the great majority of licensed medicines remain in stable supply. It also cites investment in domestic pharmaceutical manufacturing. Both statements are fair. Protocols, however, help once a shortage has been recognised, and domestic capacity is a long-horizon project. Neither addresses how quickly a problem in one trust becomes known to the system. That question grows more pressing as policy shifts care towards community settings, where dispensing points multiply and monitoring becomes harder.

The practical implications are modest in cost and clear in direction. Trust boards should expect a tested contingency plan for essential medicines and treat pharmacy supply as a standing item of operational risk. Policymakers should consider a reporting duty on trusts, designed to be light enough that it can be completed in minutes. Health-tech firms have an obvious opening in stock visibility tools, though procurement rules and fragmented systems will determine whether such tools reach the front line. Suppliers of generics, for their part, should expect closer scrutiny of resilience in contracts.

Aspirin shortages will not bring down the NHS. They do offer a cheap and early test of whether the system can detect trouble before patients feel it, and the present evidence says it cannot do so reliably. A service that cannot see its own shelves has little basis for claiming resilience.

‍